Exai Bio Appoints Dave Daly as Chief Executive Officer
24 Julio 2024 - 11:00AM
Business Wire
Exai to accelerate product development and
partnering of its novel oncRNA- and generative AI-based liquid
biopsy platform
Dave Daly brings more than 30 years of
extensive cancer diagnostics and executive leadership
experience
Exai Bio, a next-generation oncRNA- and generative AI-based
liquid biopsy company, today announced the appointment of Dave Daly
as Chief Executive Officer. With more than 30 years of cancer
diagnostics and executive leadership experience, including at
Thrive Earlier Detection (acquired by Exact Science ‘EXAS’) and
Foundation Medicine (acquired by Roche), Daly is ideally positioned
to spearhead Exai’s accelerated product development and partnering
strategy.
Exai’s liquid biopsy platform uses RNA sequencing to identify a
novel category of cancer-associated, small non-coding RNAs, termed
orphan non-coding RNAs (oncRNAs). oncRNAs are actively secreted
from living cancer cells and are abundant in the blood. When
combined with proprietary artificial intelligence, oncRNAs have
multiple advantages over tests that utilize circulating tumor DNA,
including superior sensitivity and specificity, low cost of goods,
as well as the ability to reveal dynamic changes in the biology of
a patient’s tumor over time.
“Since its founding, Exai has amassed the largest oncRNA dataset
and honed its proprietary generative AI models to deliver
unprecedented sensitivity across the major cancer types,” stated
Michael Pellini, General Partner at Section 32 and Board member of
Exai Bio. “As the company accelerates product development of its
novel platform, we are thrilled to welcome Dave Daly, who has the
deep diagnostics expertise and leadership qualities to lead the
next chapter of Exai.”
Most recently, Daly was President and Chief Operating Officer at
Singular Genomics. Prior to this role, Daly served as CEO at Thrive
Earlier Detection, a liquid biopsy company focused on multi-cancer
early detection that was acquired by Exact Sciences Corporation.
During his extensive career in diagnostics, Daly has also served in
key leadership roles at Illumina where he was Senior Vice President
and General Manager of Commercial Operations for the Americas
Region, Foundation Medicine where he was Chief Commercial Officer,
Life Technologies where he led the oncology business unit, and
Clarient where he served as Chief Commercial Officer.
“Decades spent in the diagnostics industry allowed me to clearly
see that Exai’s novel liquid biopsy platform stands out as one that
can be both truly high performing and accessible for a broad array
of patients,” stated Dave Daly, Chief Executive Officer of Exai
Bio. “I look forward to leading the team as we build our tests and
establish key partnerships that will unlock the platform’s full
potential for cancer care.”
About Exai Bio
Exai Bio is a next-generation liquid biopsy company. Its mission
is to enable a world where cancer can be detected early, diagnosed
accurately, treated in a personalized and targeted way, and
ultimately cured. The company’s proprietary oncRNA- and AI-based
liquid biopsy technology delivers clinical insights into cancer
biology to enable the earliest, most accurate diagnosis of cancer.
For more information, please visit us on www.exai.bio and follow us
on Twitter and LinkedIn.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240724591389/en/
Kim Maxwell Brown kimb@exai.bio Phone: 650-262-4516